Prehistoric teeth help create historic map of infectious diseases
Professor of evolutionary biology Eske Willerslev led the project together with associate prof Martin Sikora and prof Astrid Iversen, who is from the University of Oxford."In addition to providing information on historical conditions related to infectious diseases, the mapping also provides a deeper understanding of a number of these diseases that can still affect humans today," he said.The study uses specialised method to analyse prehistoric disease DNA.It allowed researchers to successfully map a catalogue spanning 214 known human pathogens.The researchers said the oldest sample dated back 37,000 years.Prof Iversen said that according to their analyses of ancient human remains, zoonoses "really took off" about 5,000 years ago."Zoonoses first became a major problem for humans when we started keeping animals together in large herds and living close to these animals - eating their meat and drinking their milk," she added."This meant that the animals could more easily infect each other, and that the risk of them infecting humans increased."The researchers said that approximately 70% of all new infectious diseases discovered in recent years could be transmitted from animals to humans.Known zoonoses include salmonella, rabies and MRSA.Researchers said the rise of zoonoses also showed that "the way we live has a major impact on which pathogenic microorganisms we are exposed to" and that "zoonoses are not a static phenomenon".
You can follow BBC Oxfordshire on Facebook, X (Twitter), or Instagram.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
20 minutes ago
- The Independent
Century-old pair of lungs stored in jar reveals how 1918 Spanish flu pandemic began
A pair of lungs preserved over a century ago from a deceased Spanish flu patient has helped unravel the genetic adaptations undergone by the virus to spread across Europe during the start of the 1918 pandemic. The Spanish flu pandemic of 1918-1920 was one of the most devastating pandemics in history, claiming some 20 to 100 million lives worldwide. However, little is known about how the flu virus mutated and adapted throughout the pandemic. Understanding how viruses evolved during past pandemics remains crucial for developing targeted countermeasures for the future, researchers say. Scientists have now reconstructed the first Swiss genome of the influenza virus behind the 1918 pandemic, helping unravel how it spread across Europe during its initial waves of infections. Researchers used an over 100-year-old virus sample taken from a formalin-fixed lung specimen in the Medical Collection of Switzerland's University of Zurich. The virus sample was taken from an 18-year-old patient from Zurich who died during the first wave of the pandemic in Switzerland and underwent an autopsy in July 1918. 'This is the first time we've had access to an influenza genome from the 1918–1920 pandemic in Switzerland. It opens up new insights into the dynamics of how the virus adapted in Europe at the start of the pandemic,' said Verena Schünemann, a co-author of the study from the University of Zurich. Researchers compared the Swiss genome with versions previously published from Germany and North America to find that the Swiss strain already carried three key adaptations to infect and spread among humans that would persist in the virus until the end of the pandemic. Two of these mutations seem to have made the virus more resistant to the human immune system, an important barrier against the transmission of such flu viruses originating from animals. Another mutation of a protein in the virus's membrane improved its ability to bind to entry point receptors in human cells, making it more resilient and infectious. In the study, scientists used a new method with improved ability to recover ancient RNA fragments from specimens. 'Medical collections are an invaluable archive for reconstructing ancient RNA virus genomes. However, the potential of these specimens remains underused,' said Frank Rühli, another author of the study. Researchers hope future studies using the method could lead to a better understanding of how viruses adapt to humans during a pandemic, enabling us to better anticipate and adapt to future pandemics.
The Independent
an hour ago
- The Independent
The vaccine that could lower the risk of dementia by 20 per cent
Over the past two centuries, vaccines have been critical for preventing infectious diseases. The World Health Organization estimates that vaccination prevents between 3 million and 5 million deaths annually from diseases like diphtheria, tetanus, influenza, measles and, more recently, COVID-19. While there has long been broad scientific consensus that vaccines prevent or mitigate the spread of infections, there is new research suggesting that the therapeutic impact might go beyond the benefit of preventing infectious diseases. An April 2025 study published in the prominent journal Nature found tantalizing evidence that the herpes zoster – or shingles – vaccine could lower the risk of dementia in the general population by as much as 20%. We are a team of physician scientists with expertise in the clinical and basic science of neurodegenerative disorders and dementia. We believe that this study potentially opens the door to other breakthroughs in understanding and treating dementia and other degenerative disorders of the brain. A role for vaccines in reducing dementia risk? One of the major challenges researchers face when trying to study the effects of vaccines is finding an unvaccinated 'control group' for comparison – a group that is similar to the vaccine group in all respects, save for the fact that they haven't received the active vaccine. That's because it's unethical to assign some patients to the control group and deprive them of vaccine protection against a disease such as shingles. The Nature study took advantage of a policy change in Wales that went into effect in 2013, stating that people born on or after September 2, 1933, were eligible for the herpes zoster vaccination for at least a year, while those born before that cutoff date were not. The vaccine was administered to prevent shingles, a painful condition caused by the same virus that causes chickenpox, which can lie dormant in the body and be reactivated later in life. The researchers used the policy change as a natural laboratory of sorts to study the effect of shingles vaccination on long-term health outcomes. In a statistically sophisticated analysis of health records, the team found that the vaccine reduced the probability of getting dementia by one-fifth over a seven-year period. This means that people who received the shingles vaccine were less likely to develop clinical dementia over the seven-year follow-up period, and women benefited more than men. The study design allowed researchers to compare two groups without actively depriving any one group of access to vaccination. The two groups were also of comparable age and had similar medical comorbidities – meaning similar rates of other medical conditions such as diabetes or high blood pressure. Results from this and other related studies raise the possibility that vaccines may have a broader role in experimental therapeutics outside the realm of infectious diseases. These studies also raise provocative questions about how vaccines work and how our immune system can potentially prevent dementia. How vaccines might be protective One scientific explanation for the reduction of dementia by the herpes zoster vaccine could be the direct protection against the shingles virus, which may play a role in exacerbating dementia. However, there is also the possibility that the vaccine may have conferred protection by activating the immune system and providing 'trained immunity,' in which the immune system is strengthened by repeated exposure to vaccines or viruses. The study did not differentiate between different types of dementia, such as dementia due to Alzheimer's disease or dementia due to stroke. Additionally, researchers cannot draw any definitive conclusions about possible mechanisms for how the vaccines could be protective from an analysis of health records alone. The next step would be a prospective, randomized, double-blind, placebo-controlled study – the 'gold standard' for clinical trials in medicine – to directly examine how the herpes zoster vaccine compares with a placebo in their ability to reduce the risk of dementia over time. Such studies are necessary before any vaccines, as well as other potential therapies, can be recommended for routine clinical use in the prevention of dementia. The challenges of untangling dementia Dementia is a major noncommunicable disease that is a leading cause of death around the world. A January 2025 study provided updated figures on lifetime dementia risk across different subsets of the U.S. population. The researchers estimate that the lifetime risk of dementia after age 55 is 42% – more than double earlier estimates. The dementia risk was 4% by age 75, and 20% by age 85, with the majority of risk occurring after 85. The researchers projected that the number of new cases of dementia in the U.S. would double over the next four decades from approximately 514,000 cases in 2020 to 1 million in 2060. Once considered a disease largely confined to the developed world, the deleterious effects of dementia are now apparent throughout the globe, as life expectancy increases in many formerly developing countries. While there are different forms of dementia with varying clinical manifestations and underlying neurobiology, Alzheimer's disease is the most common. Prospective studies that specifically test how giving a vaccine changes the risk for future dementia may benefit from studying patient populations with specific types of dementia because each version of dementia might require distinct treatments. Unfortunately, for the past two to three decades, the amyloid hypothesis of Alzheimer's disease – which posits that accumulation of a protein called amyloid in the brain contributes to the disorder – dominated the scientific conversation. As a result, most of the efforts in the experimental therapeutics of Alzheimer's disease have focused on drugs that lower the levels of amyloid in the brain. However, results to date have been modest and disappointing. The two recently approved amyloid-lowering therapies have only a minimal impact on slowing the decline, are expensive and have potentially serious side effects. And no drug currently approved by the Food and Drug Administration for clinical use reverses the cognitive decline. Studies based on health records suggest that past exposure to viruses increases the risk of dementia, while routine vaccines, including those against tetanus, diphtheria, pertussis, pneumonia, shingles and others, reduce the risk. Innovation and an open mind There is sometimes a tendency among scientists to cling to older, familiar models of disease and a reluctance to move in more unconventional directions. Yet the process of doing science has a way of teaching researchers like us humility, opening our minds to new information, learning from our mistakes and going where that data takes us in our quest for effective, lifesaving therapies. Vaccines may be one of those paths less traveled. It is an exciting possibility that may open the door to other breakthroughs in understanding and treating degenerative disorders of the brain. Anand Kumar is a Professor and Department Head of Psychiatry at the University of Illinois Chicago. Jalees Rehman is Department Chair and Professor of Biochemistry and Molecular Genetics at the University of Illinois Chicago.
Telegraph
an hour ago
- Telegraph
Prostate cancer breakthrough cuts risk of erectile dysfunction
Men having prostate cancer treatment could be spared erectile dysfunction thanks to a breakthrough. The ERECT trial, investigating methods to preserve erectile function in men undergoing treatment, treated them using MRI-guided radiotherapy. This method targets the prostate while avoiding the nerves and blood vessels needed for erections. Erectile dysfunction is one of the most common side-effects of prostate cancer treatment, especially following radiotherapy or surgery. Treatments can affect the nerves and blood vessels involved in achieving and maintaining an erection, leading to varying degrees of sexual dysfunction in many patients. The study, by University Medical Centre Utrecht, found the targeted method had less than half the risk of erectile dysfunction compared with standard techniques. In the UK, prostate cancer is the most common cancer in men. Each year, approximately 55,000 men are diagnosed with it and, despite advances in detection and treatment, around 12,000 die from the disease annually with around 10,000 deaths a year in England. The incidence of prostate cancer has been rising, partly because of increased awareness and PSA testing. However, survival rates have also improved significantly. Nearly 80 per cent of men diagnosed with prostate cancer today are expected to survive for at least 10 years. The Telegraph is campaigning for the introduction of targeted screening for prostate cancer. Health advisers are currently considering the evidence for rolling out screening that could target tests to those at increased risk of the disease, such as black men or those with a family history of the disease. However, getting the focus right is crucial. Too many false positives can lead to over treatment of slow-growing disease, which can mean needless potentially distressing side-effects. Dr Jochem van der Voort van Zyp, the lead investigator, said: 'With MRI guidance, we limit radiation to erectile tissues but still treat the prostate effectively. With the enhanced precision of MRI guidance, we gain the confidence to limit the dose these erectile tissues receive. 'The prostate gets the therapeutic dose while the erectile tissues receive a much lower dose, thus preserving their function.' The trial of 70 men found that, at six months, six per cent had erectile dysfunction, compared to 21 per cent with conventional treatment. After 18 months, 16 per cent experienced dysfunction compared to 36 per cent in the control group. Experts said the new technique could offer men a better chance of maintaining sexual function following prostate cancer treatment without compromising cancer control. It is estimated that more than 16,000 men a year – those with low to intermediate risk disease – who receive radiotherapy could potentially benefit from such advances. So far, the technology is being used at the The Royal Marsden NHS Foundation Trust and The Christie NHS Foundation Trust in Manchester, with plans for rollout to two more sites. The device used, the Elekta Unity MR-Linac, combines MRI with radiation delivery for precise treatment. It allows doctors to see the prostate and surrounding tissues in detail and adjust treatment in real-time to avoid damaging healthy structures. John Christodouleas, Elekta's senior vice president of medical affairs, said: 'These results add to growing evidence that minimising radiation to normal tissues improves quality of life for men with prostate cancer.' Elekta Unity MR-Linac is the world's first and only device to combine a high-field MRI with a state-of-the-art linear accelerator. Experts said that enabled clinicians to use imaging to guide radiation delivery to tumour targets and avoid surrounding structures. In addition, while treatment is ongoing, the system allows clinicians to non-invasively monitor the position of the target. If, for example, if the prostate shifts because of motion of the bowels or bladder filling, the radiation treatment can be discontinued to avoid unnecessary radiation to surrounding normal tissues. The preliminary results were presented by clinicians from University Medical Centre Utrecht at the European Society for Radiotherapy and Oncology annual congress earlier this year.
